Class: Heparins
- Low molecular weight Heparins
- LMWHs
CAS Number: 9005-49-6
Medically reviewed by Drugs.com. Last updated on Oct 13, 2020.
Warning
- Spinal/Epidural Hematoma Risk
-
Epidural or spinal hematomas and neurologic injury, including long-term or permanent paralysis, associated with concurrent use of low molecular weight heparins (LMWHs) or heparinoids and neuraxial (spinal/epidural) anesthesia or spinal puncture.1 26 142
-
Risk increased by use of indwelling epidural catheters or by concomitant use of drugs affecting hemostasis (e.g., NSAIAs, platelet-aggregation inhibitors, other anticoagulants).1 26 142 143
-
Risk also increased by history of traumatic or repeated epidural or spinal puncture, spinal deformity, or spinal surgery.1 26
-
Optimal timing between administration of enoxaparin and neuraxial procedures not known.1
-
Monitor frequently for signs and symptoms of neurologic impairment and treat urgently if neurologic compromise noted.1 26 142 143
-
Consider potential benefits versus risks of spinal or epidural anesthesia or spinal puncture in patients receiving or being considered for thromboprophylaxis with anticoagulants.1 26 (See Spinal/Epidural Hematomas under Cautions.)
Introduction
Anticoagulant; an LMWH.1 2 3 4
Uses for Enoxaparin
Thromboprophylaxis in General/Abdominal Surgery
Prevention of postoperative DVT, which may lead to PE, in patients undergoing general/abdominal surgery who are at risk for thromboembolic complications.1
The American College of Chest Physicians (ACCP) recommends pharmacologic (e.g., LMWH) and/or nonpharmacologic/mechanical (e.g., intermittent pneumatic compression) methods of thromboprophylaxis in patients undergoing general surgery, including abdominal, GI, gynecologic, and urologic surgery, according to the patient’s risk of thromboembolism and bleeding.1002 In general, pharmacologic prophylaxis is recommended in patients with high (and possibly moderate) risk of venous thromboembolism who do not have a high risk of bleeding, while mechanical methods are suggested in patients who require thromboprophylaxis but have a high risk of bleeding.1002
If pharmacologic prophylaxis is used in patients undergoing general surgery, ACCP states that an LMWH or low-dose heparin (“heparin” referring throughout this monograph to unfractionated heparin) is preferred.1002
Because risk of venous thromboembolism is particularly high in patients undergoing abdominal or pelvic surgery for cancer, extended (4 weeks) prophylaxis with an LMWH is recommended in such patients.1002
ACCP states that the recommendations for use of antithrombotic agents in general surgery patients can be applied to patients undergoing bariatric, vascular, and plastic/reconstructive surgery.1002
Thromboprophylaxis in Hip-Replacement, Knee-Replacement, or Hip-Fracture Surgery
Prevention of postoperative DVT, which may lead to PE, in patients undergoing hip-replacement surgery.1 2 3 5 6 7 20 21 22 27 34 35 36 37 38 1003
Prevention of DVT and/or PE in patients undergoing knee-replacement surgery.1 20 22 1003
Also has been used for thromboprophylaxis in patients undergoing hip-fracture surgery†.1003
ACCP recommends routine thromboprophylaxis (with a pharmacologic and/or mechanical method) in all patients undergoing major orthopedic surgery because of high risk of postoperative venous thromboembolism; continue thromboprophylaxis for at least 10–14 days, and possibly for up to 35 days after surgery†.1003
Several antithrombotic agents (e.g., LMWHs, fondaparinux, low-dose heparin, warfarin, aspirin) recommended by ACCP for pharmacologic prophylaxis during major orthopedic surgery.1003 When selecting an appropriate thromboprophylaxis regimen, consider factors such as efficacy, safety, logistics, and compliance.1003
Medical Conditions Predisposing to Thromboembolism
Prevention of DVT, which may lead to PE, in patients with severely restricted mobility during acute illness.1 2 3 5 6 7 20 21 22 27 34 35 36 37 1001
In general, pharmacologic thromboprophylaxis recommended only in patients considered to be at high risk of venous thromboembolism.1001
ACCP recommends anticoagulant prophylaxis (e.g., LMWH) in acutely ill, hospitalized medical patients at increased risk of thrombosis who are not actively bleeding and do not have an increased risk of bleeding.1001 Continued thromboprophylaxis suggested for 6–21 days until full mobility is restored or hospital discharge, whichever comes first.1001
Use of LMWHs also suggested by ACCP for pharmacologic thromboprophylaxis in critically ill patients (e.g., those in an intensive care unit [ICU]) who are not actively bleeding and do not have risk factors for bleeding.1001
Risk of venous thromboembolism is particularly high in patients with cancer.1001 Use of LMWH prophylaxis suggested by ACCP in cancer outpatients with solid tumors who have additional risk factors for thromboembolism, provided risk of bleeding is low.1001
Treatment and Secondary Prevention of Acute DVT and/or PE
Inpatient treatment of acute DVT with or without PE when administered in conjunction with warfarin.1 28 1005
Outpatient treatment of acute DVT without PE when administered in conjunction with warfarin.1 28 1005
Recommended by ACCP as an appropriate choice of anticoagulant for initial treatment of acute proximal DVT and/or PE.1005
LMWHs or fondaparinux generally preferred over heparin for initial treatment of acute venous thromboembolism; however, heparin may be preferred in patients with renal impairment.1005 IV heparin also may be preferred over LMWH in patients with PE in whom thrombolytic therapy is being considered or if there is concern about adequate sub-Q absorption.1005
For long-term anticoagulant therapy (secondary prevention), warfarin generally preferred in patients without cancer; however, in patients with cancer, ACCP suggests use of an LMWH because of a possible reduced response to warfarin in such patients.1005
Continue anticoagulant therapy for at least 3 months, and possibly longer depending on individual clinical situation.1005
Non-ST-Segment-Elevation Acute Coronary Syndromes (NSTE ACS)
Reduction in the risk of acute cardiac ischemic events (death, MI) in patients with NSTE ACS (unstable angina or non-ST-segment-elevation MI [NSTEMI]) when administered concurrently with aspirin and/or other standard therapy (e.g., nitrates, β-adrenergic blocking agents [β-blockers], clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors).1 40 41 42 43 48 53 146 991 1100
Initial parenteral anticoagulants with established efficacy in patients with NSTE ACS include enoxaparin, heparin, bivalirudin (only in patients managed with an early invasive strategy), and fondaparinux.1100
Also used in patients with NSTE ACS undergoing PCI to prevent thrombus formation during the procedure.994
ST-Segment-Elevation MI (STEMI)
Used as adjunctive therapy for the management of acute STEMI in patients receiving thrombolysis and being managed medically or with PCI.1 162 164 165 527 994
ACCF and AHA state that patients with STEMI undergoing thrombolytic therapy should receive an anticoagulant (e.g., heparin, enoxaparin, fondaparinux) for ≥48 hours, and preferably for the duration of the index hospitalization, up to 8 days or until revascularization is performed.527 Enoxaparin is preferred over heparin if extended anticoagulation (>48 hours) is necessary.527
Adjunctive use of an LMWH in patients with acute STEMI associated with improvement in short-term clinical outcomes (e.g., death, reinfarction, recurrent ischemia) with generally similar rates of bleeding complications compared with adjunctive heparin or placebo.129 130 131 132 133
Also used in patients with STEMI undergoing PCI to prevent thrombus formation during the procedure.1 994 There is less experience with enoxaparin in the setting of primary PCI†.527
Treatment of Superficial Vein Thrombosis
LMWHs also have been used for treatment of spontaneous superficial vein thrombosis (superficial thrombophlebitis)†; ACCP suggests use of prophylactic dosages for 45 days in patients with superficial vein thrombosis of ≥5 cm in length.1005
Thromboprophylaxis in Cardiac Surgery
Mechanical methods of prophylaxis generally recommended in patients undergoing cardiac surgery; however, ACCP states that an LMWH may be considered for thromboprophylaxis in cardiac surgery patients† with a complicated postoperative course.1002
Thromboprophylaxis in Thoracic Surgery
Pharmacologic thromboprophylaxis (e.g., LMWH) recommended by ACCP in patients undergoing thoracic surgery† who are at high risk of venous thromboembolism, provided risk of bleeding is low.1002
Thromboprophylaxis in Neurosurgery
LMWHs have been used for prevention of venous thromboembolism in patients undergoing craniotomy†; however, benefits of such prophylaxis may be outweighed by possible increased risk of intracranial hemorrhage.1002 ACCP states that LMWH prophylaxis may be considered in patients at very high risk of thromboembolism (e.g., those undergoing craniotomy for malignant disease) once adequate hemostasis established and risk of bleeding decreases.1002
Thromboprophylaxis with LMWHs also may be considered in high-risk patients undergoing spinal surgery† (e.g., those with malignancy or those undergoing surgery with a combined anterior-posterior approach) once adequate hemostasis established and risk of bleeding decreases.1002
Thromboprophylaxis in Trauma
May be used for thromboprophylaxis in patients with major trauma†.1002 For major trauma patients at high risk of venous thromboembolism, including those with acute spinal cord injury, traumatic brain injury, or spinal surgery for trauma, ACCP suggests use of both a pharmacologic and mechanical method of prophylaxis, unless contraindications exist.1002
Treatment of Renal Vein Thrombosis
Although use of anticoagulant therapy for renal vein thrombosis† (most common cause of spontaneous venous thromboembolism in neonates) is controversial, LMWHs are suggested by ACCP as a possible treatment option in selected neonates.1013
Thromboprophylaxis in Acute Ischemic Stroke
Heparin anticoagulants (i.e., LMWH or heparin) have been used for thromboprophylaxis in selected patients with acute ischemic stroke†; those with additional risk factors for venous thromboembolism are more likely to benefit from such prophylaxis.1009
ACCP suggests thromboprophylaxis with an LMWH, sub-Q heparin, or intermittent pneumatic compression in patients with acute ischemic stroke† and restricted mobility; LMWH is preferred over heparin.1009
Prophylactic-dose heparin (heparin or an LMWH) usually initiated within 48 hours of onset of stroke and continued throughout hospital stay until patient regains mobility; do not administer within the first 24 hours after thrombolytic therapy.1009
LMWHs also recommended by ACCP as an option for initial management of acute arterial ischemic stroke in children† until dissection and embolic causes have been excluded.1013 If arterial ischemic stroke is associated with dissection or a cardioembolic origin, continued anticoagulant therapy suggested.1013
In children with acute arterial ischemic stroke secondary to non-Moyamoya vasculopathy†, ACCP recommends ongoing antithrombotic therapy (e.g., with an LMWH) for 3 months.1013
LMWHs may be considered in neonates with a first episode of arterial ischemic stroke associated with a documented cardioembolic source†.1013
Thromboembolism During Pregnancy
Used during pregnancy for prevention and treatment of venous thromboembolism†, and for prevention and treatment of systemic embolism associated with mechanical heart valves.138 996 1012 (See Treatment and Prevention of Thromboembolism During Pregnancy under Dosage and Administration.)
Also has been used in combination with low-dose aspirin for prevention of recurrent pregnancy loss in women with antiphospholipid antibody (APLA) syndrome†.1012
LMWHs (rather than heparin or warfarin) are recommended by ACCP for prevention and treatment of thromboembolism during pregnancy†.1012
In pregnant women with an acute venous thromboembolic event†, ACCP recommends an LMWH for initial treatment and secondary prevention throughout the remainder of the pregnancy.1012 To prevent recurrence of postpartum anticoagulation (for ≥6 weeks and for a total duration of ≥3 months) is suggested.1012
In general, thromboprophylaxis (e.g., with an LMWH) is suggested during the antepartum period only in pregnant women who have a history of thromboembolism† and are considered to be at moderate to high risk of recurrent events (e.g., those with a single episode of unprovoked venous thromboembolism, pregnancy- or estrogen-related venous thromboembolism, history of multiple unprovoked events).1012
Postpartum thromboprophylaxis† for 6 weeks is suggested in all pregnant women with a prior venous thromboembolic event; an LMWH (in prophylactic or intermediate dosages) or warfarin (INR 2–3) may be used for such prophylaxis.1012
Hereditary thrombophilias substantially increase risk of pregnancy-related venous thromboembolism; a family history of venous thromboembolism further increases risk.1012 ACCP suggests antepartum and postpartum prophylaxis with an LMWH in some pregnant women with high-risk hereditary thrombophilias (e.g., homozygous genetic mutations for factor V Leiden or prothrombin G20210A) who have not experienced a prior venous thromboembolic event, but have a family history of thromboembolism†.1012
An LMWH has been used in combination with low-dose aspirin for prevention of pregnancy loss in women with antiphospholipid antibodies (APLA) syndrome and recurrent (3 or more) pregnancy loss†.138 1012
Discontinue LMWH therapy ≥24 hours prior to induction of labor or cesarean section (or expected time of neuraxial anesthesia) to avoid an unwanted anticoagulant effect on fetus.1012
Cardioversion of Atrial Fibrillation/Flutter
LMWHs have been used for prevention of stroke and systemic embolism in patients with atrial fibrillation or atrial flutter undergoing electrical or pharmacologic cardioversion†.999 1007
As an alternative to prolonged anticoagulation (e.g., usually with warfarin) prior to cardioversion in patients with atrial fibrillation lasting >48 hours or of unknown duration, LMWHs (in therapeutic dosages) may be used at the time of transesophageal echocardiography (TEE), followed by cardioversion within 24 hours if no thrombus is detected.999 1007
In patients with atrial fibrillation of short duration (e.g., ≤48 hours), LMWHs (in therapeutic dosages) may be used at presentation, followed by immediate cardioversion.1007
In patients with hemodynamic instability who require urgent cardioversion, ACCP suggests administration of a parenteral anticoagulant (in therapeutic dosages) prior to cardioversion, if possible; however, such anticoagulant therapy must not delay any emergency intervention.999 1007
After successful cardioversion to sinus rhythm, all patients should receive therapeutic anticoagulation for ≥4 weeks.999 1007
Thromboprophylaxis in Patients with Prosthetic Heart Valves
Used during conversion to maintenance therapy with warfarin to reduce the incidence of thromboembolism in patients with prosthetic mechanical heart valves†.64 83 87 90 93 97 98 1008
ACCP suggests bridging anticoagulation (an LMWH in either prophylactic or therapeutic dosages or IV heparin in prophylactic dosages) during the early postoperative period after insertion of a mechanical heart valve in patients without bleeding risk, until an adequate response to warfarin is obtained.1008
Also may be used for bridging anticoagulation in patients with a mechanical heart valve in whom therapy with warfarin must be temporarily discontinued (e.g., those undergoing major surgery).1004
Has been used for thromboprophylaxis in pregnant women with prosthetic mechanical heart valves†.138 1012 (See Thromboembolism During Pregnancy under Uses.)
Venous Thromboembolism in Pediatric Patients
An LMWH has been used for treatment and secondary prevention of venous thromboembolism in pediatric patients†; venous thromboembolism usually occurs secondary to an identifiable risk factor (e.g., presence of central venous access device) in such patients.1013
Recommendations regarding use of antithrombotic therapy in children generally based on extrapolation from adult guidelines.1013
ACCP recommends an LMWH or heparin for both initial and ongoing treatment of venous thromboembolism in children.1013 Potential advantages of an LMWH over heparin include reduced need for monitoring, lack of drug or dietary interactions, reduced risk of heparin-induced thrombocytopenia (HIT), and possible reduced risk of osteoporosis.1013
In children with central venous catheter-related thromboembolism, ACCP recommends removal of catheter if no longer functioning or required; at least 3–5 days of therapeutic anticoagulation is suggested prior to removal.1013 If such catheters must remain in place, ACCP suggests anticoagulant therapy until catheter is removed.1013
Treatment of Cerebral Venous Sinus Thrombosis
May be used for the treatment of acute cerebral venous sinus (sinovenous) thrombosis† in adults.1009 Once patient is stable, may convert to coumarin anticoagulant therapy.138 1009
Reasonable to use full-dose LMWH rather than heparin for treatment of acute cerebral venous sinus thrombosis during pregnancy.1017 Prophylaxis with an LMWH during pregnancy and the postpartum period is reasonable in women with history of cerebral venous sinus thrombosis.1017
Recommended by ACCP as an option for initial and follow-up anticoagulation in children with cerebral venous sinus thrombosis† without substantial intracranial hemorrhage.1013 Also has been suggested for use in children with substantial hemorrhage.1013
LMWHs also suggested by ACCP as a treatment option for neonates with cerebral sinovenous thrombosis†.1013
Perioperative Antithrombotic Prophylaxis
ACCP suggests use of an LMWH or IV heparin during temporary interruption of warfarin therapy (bridging anticoagulation†) in selected patients with venous thromboembolism, atrial fibrillation, or mechanical prosthetic heart valves undergoing surgery or other invasive procedures; use and type of bridging anticoagulation depend on patient's risk of developing thromboembolism without warfarin therapy.1004
In general, bridging anticoagulation is suggested in such patients who are considered to be at particularly high risk of venous thromboembolism without oral anticoagulant therapy.1004
Enoxaparin Dosage and Administration
General
-
Since routine coagulation parameters such as PT or aPTT are insensitive for monitoring enoxaparin activity, routine monitoring of coagulation parameters generally not required.1
-
Monitoring of anti-factor Xa levels may be helpful in high-risk groups, such as pregnant patients, patients with renal impairment, patients at extremes of weight, or if abnormal coagulation parameters or bleeding occurs during treatment.1 128 135
-
If an LMWH is used for anticoagulation in children, ACCP suggests that dosage be adjusted to a target anti-factor Xa level of 0.5–1 units/mL based on a sample taken 4–6 hours, or 0.5–0.8 units/mL based on a sample taken 2–6 hours, following sub-Q administration.1013
-
In patients with unstable angina or NSTEMI, adhere precisely to intervals recommended between doses to minimize the risk of bleeding.1 If a closure device is used, may remove sheath immediately after PCI.1 Otherwise, if a manual compression method is used, remove vascular access sheath 6 hours following the last dose of enoxaparin sodium.1 If continuing enoxaparin sodium therapy, administer the next scheduled dose no sooner than 6–8 hours after sheath removal.1 Observe procedure site for signs of bleeding or hematoma formation.1
Administration
Administer by deep sub-Q injection for most indications; do not give IM.1
In patients with acute STEMI, administer as single-dose direct IV (“bolus”) injection followed by sub-Q administration.1 162 Direct IV injection† also used in selected patients with unstable angina or NSTEMI undergoing PCI.136 994
When using multiple-dose vials, withdraw the dose using a tuberculin or equivalent syringe.1
Do not mix enoxaparin with other injections or infusions.1
IV Administration
May be administered by direct IV injection into an IV line.1 Use multiple-dose vial for IV administration.1
To avoid mixing IV enoxaparin with other drugs, flush IV line with a sufficient amount of 0.9% sodium chloride injection or 5% dextrose injection prior to and following IV administration of enoxaparin.1
Sub-Q Administration
Patient should be supine during administration.1 17
To avoid loss of drug when using the 30- or 40-mg prefilled syringes, do not expel air from syringe prior to injection.1
Inject drug sub-Q into the left and right anterolateral and left and right posterolateral abdominal wall.1
Insert the entire length of the needle into a skin fold created by the thumb and forefinger; hold the skin fold until the needle is withdrawn.1
Alternate injection sites frequently.1
To minimize bruising, do not massage injection sites after injection.1
Dosage
Available as enoxaparin sodium; dosage expressed in terms of the salt.100
Dosages for enoxaparin sodium or other LMWHs and heparin cannot be used interchangeably on a unit-for-unit (or mg-for-mg) basis.1
Available as enoxaparin sodium.1 Enoxaparin sodium has an approximate anti-factor Xa activity of 100 units/mg using the WHO First International Low Molecular Weight Heparin Reference Standard.1
Adults
Prevention of DVT and/or PE
General/Abdominal Surgery
Sub-Q40 mg once daily initiated 2 hours prior to surgery.1
Usual duration of therapy is 7–10 days, although up to 12 days of treatment has been well tolerated in clinical trials.1 71
Extended prophylaxis (for up to 4 weeks) recommended by ACCP in patients undergoing abdominal or pelvic surgery for cancer.1002
Hip-Replacement Surgery
Sub-Q30 mg every 12 hours initiated 12–24 hours after surgery, provided hemostasis has been established.1
Alternatively, may consider dosage of 40 mg once daily, initiated approximately 12 hours before surgery.1
Because of risk of bleeding, ACCP recommends that LMWHs be initiated at least 12 hours preoperatively or at least 12 hours postoperatively in patients undergoing major orthopedic surgery.1003
Continue prophylaxis throughout the postoperative period, generally for 7–10 days, until risk of DVT has diminished; manufacturer states that up to 14 days of thromboprophylaxis was well tolerated in clinical trials.1
Following the initial phase of thromboprophylaxis during the acute postoperative period, manufacturer recommends continued prophylaxis with 40 mg once daily for 3 weeks.150
ACCP recommends a minimum of 10–14 days of thromboprophylaxis, and suggests extending prophylaxis for up to 35 days on an outpatient basis.1003
Knee-Replacement Surgery
Sub-Q30 mg every 12 hours initiated 12–24 hours after surgery, provided hemostasis has been established.1
Because of risk of bleeding, ACCP recommends that LMWHs be initiated at least 12 hours preoperatively or 12 hours postoperatively in patients undergoing major orthopedic surgery.1003
Continue prophylaxis throughout the postoperative period, generally for 7–10 days, until risk of DVT has diminished; manufacturer states that up to 14 days of thromboprophylaxis was well tolerated in clinical trials.1
ACCP recommends a minimum of 10–14 days of thromboprophylaxis, and suggests extending prophylaxis for up to 35 days on an outpatient basis.1003
Medical Conditions Predisposing to Thromboembolism
Sub-QAcute illness with severely restricted mobility (e.g., cancer, heart failure, severe lung disease, patients confined to bedrest): 40 mg once daily.1 Usual duration of therapy is 6–11 days; well tolerated for up to 14 days in clinical trials.1
ACCP suggests against the use of extended thromboprophylaxis beyond the period of patient immobilization or acute hospital stay in acutely ill medical patients.1001
Treatment of DVT with or without PE
Sub-Q
Outpatient treatment at home in patients without PE: 1 mg/kg every 12 hours.1 29
Inpatient (hospital) treatment in patients with or without PE (who are not candidates for outpatient treatment): 1 mg/kg every 12 hours or 1.5 mg/kg once daily at the same time every day.1
Average duration of therapy is 7 days, although up to 17 days of treatment has been well tolerated in clinical trials.1
Initiate concurrent warfarin therapy when appropriate, usually within 72 hours of enoxaparin injection.1 ACCP recommends initiating warfarin on the first treatment day and overlapping therapy with warfarin and enoxaparin for ≥5 days and until the INR is at least 2 for ≥24 hours.1005
NSTE ACS
Sub-Q
1 mg/kg every 12 hours in conjunction with aspirin therapy (100–325 mg once daily).1
Initiate as soon as possible after hospital admission.991 Administer for a minimum of 2 days and continue until clinical stabilization.1 41 42
Usual duration of treatment is 2–8 days, although up to 12.5 days of treatment has been well tolerated in clinical trials.1 41 42
Patients undergoing PCI who have not received prior anticoagulant therapy: ACCF/AHA/SCAI state that it is reasonable to administer enoxaparin sodium (e.g., 0.5–0.75 mg/kg by direct IV injection) at the time of PCI†.994
Patients in whom sub-Q enoxaparin has been initiated prior to PCI (“upstream”): ACCF/AHA/SCAI state that an additional 0.3-mg/kg dose of enoxaparin sodium should be given by direct IV injection at the time of PCI if fewer than 2 prior therapeutic (e.g., 1 mg/kg) sub-Q doses of enoxaparin sodium have been given or if the last sub-Q dose of the drug was administered 8–12 hours before PCI†.994
To minimize the possibility of bleeding associated with vascular (e.g., vascular access sheath) instrumentation (e.g., PCI), adhere strictly to dosage intervals and observe precautions in removing vascular access sheath.1 Administer next dose of enoxaparin sodium no sooner than 6–8 hours after removal of vascular access sheath;1 ACCF/AHA/SCAI suggest removal of femoral sheath when ACT falls to <150–180 seconds or aPTT falls to <50 seconds.994 Monitor vascular access sites carefully for signs of bleeding or hematoma formation after removal of vascular sheath and during enoxaparin treatment.1
STEMI
IV, then Sub-Q
Initial dose in patients <75 years of age: 30 mg by direct IV injection. Follow with 1 mg/kg sub-Q every 12 hours (maximum 100 mg per dose for each of the first 2 sub-Q doses, then 1 mg/kg per dose thereafter);1 give first sub-Q dose immediately after direct IV dose.1 (See Geriatric Patients under Dosage and Administration for dosing recommendations in patients ≥75 years of age.)
When used with thrombolytic therapy, initiate enoxaparin therapy 15 minutes before to 30 minutes after initiation of thrombolytic therapy.1
Manufacturer states optimal duration not known but likely to be >8 days; enoxaparin therapy was continued for 8 days or until hospital discharge in clinical trials.1
Use in conjunction with aspirin therapy (75–325 mg once daily) unless contraindicated.1
Patients undergoing PCI: If last sub-Q dose of enoxaparin sodium was administered ≥8 hours before PCI, manufacturer recommends an additional 0.3-mg/kg dose by direct IV injection during PCI.1 166 167
To minimize the possibility of bleeding associated with vascular (e.g., vascular access sheath) instrumentation (e.g., PCI), adhere strictly to dosage intervals and observe precautions in removing vascular access sheath.1 Administer next dose of enoxaparin sodium no sooner than 6–8 hours after removal of vascular access sheath.1 ACCF/AHA/SCAI suggest removal of femoral sheath after PCI when ACT falls to <150–180 seconds or aPTT falls to <50 seconds.994 Monitor vascular access sites carefully for signs of bleeding or hematoma formation after removal of vascular sheath and during enoxaparin treatment.1
Treatment and Prevention of Thromboembolism During Pregnancy†
Sub-Q
Treatment of acute venous thromboembolism: 1 mg/kg every 12 hours for the remainder of pregnancy; continue anticoagulation for ≥6 weeks postpartum (minimum total duration of 3 months).1012
Postpartum prophylaxis in pregnant women with a prior venous thromboembolic event: Prophylactic (40 mg once daily) or intermediate (40 mg every 12 hours) dosage suggested.1012
Pregnant women receiving long-term coumarin anticoagulation (e.g., warfarin): An LMWH may be used throughout pregnancy in a weight-adjusted dosage (e.g., enoxaparin sodium 1 mg/kg every 12 hours) or 75% of a weight-adjusted dosage; resume long-term anticoagulation postpartum.1012
Primary prevention of venous thromboembolism in pregnant women with high-risk thrombophilias: Prophylactic (40 mg once daily) or intermediate (40 mg every 12 hours) dosage suggested.1012
Pregnant women with APLA syndrome: Antepartum administration of an LMWH in prophylactic dosages recommended by ACCP; combine with low-dose aspirin (75–100 mg daily).1012
Pregnant women with mechanical heart valves: ACCP recommends an LMWH throughout pregnancy or, alternatively, an LMWH until 13th week of pregnancy, substituting warfarin until close to delivery, then resuming LMWH therapy.1012 Twice-daily administration recommended because of altered pharmacokinetics in pregnant women, with adjustment of enoxaparin sodium dosage to maintain anti-factor Xa levels of 0.7–1.2 units/mL 4 hours after dosing.996 Resume usual long-term anticoagulation postpartum.1012 (See Patients with Mechanical Heart Valves under Cautions.)
Consider use of a shorter-acting anticoagulant as delivery approaches.1 To avoid an unwanted anticoagulant effect on the fetus during delivery, discontinue LMWH ≥24 hours prior to induction of labor or cesarean section.1012
Cardioversion of Atrial Fibrillation/Flutter†
Sub-Q
For prevention of stroke and systemic embolism in patients undergoing cardioversion for atrial fibrillation or atrial flutter†, use of full venous thromboembolism treatment dosages recommended.1007
Perioperative Antithrombotic Prophylaxis†
Sub-Q
For bridging anticoagulation during temporary interruption of warfarin therapy in patients undergoing surgery or other invasive procedures, ACCP generally recommends therapeutic dosages of a LMWH (e.g., enoxaparin sodium 1 mg/kg twice daily or 1.5 mg/kg once daily).1004
Special Populations
Hepatic Impairment
No special population dosage recommendations at this time.1
Renal Impairment
Use with caution in renally impaired patients.1 3 128 No dosage adjustments necessary in patients with mild (Clcr 50–80 mL/minute) or moderate (Clcr 30–50 mL/minute) renal impairment.1
Adjust dosage for patients with severe renal impairment (Clcr <30 mL/minute).1 1000
DVT and/or PE
Thromboprophylaxis in General/Abdominal Surgery
Sub-QIn patients with severe renal impairment (Clcr <30 mL/minute), 30 mg once daily.1
Thromboprophylaxis in Hip- or Knee-Replacement Surgery
Sub-QIn patients with severe renal impairment (Clcr <30 mL/minute), 30 mg once daily.1
Thromboprophylaxis in Medical Conditions Associated with Thromboembolism
Sub-QIn patients with severe renal impairment (Clcr <30 mL/minute), 30 mg once daily.1
Treatment of DVT with or without PE
Sub-QIn patients with severe renal impairment (Clcr <30 mL/minute), 1 mg/kg once daily in conjunction with warfarin therapy.1
NSTE ACS
Sub-Q
In patients with severe renal impairment (Clcr <30 mL/minute), 1 mg/kg once daily with concurrent aspirin therapy (100–325 mg once daily).1
STEMI
IV and Sub-Q
In patients with severe renal impairment (Clcr <30 mL/minute) who are <75 years of age: 30 mg as a single direct IV dose, followed by 1 mg/kg sub-Q once daily (not to exceed 100 mg per dose for the first 2 sub-Q doses) with concurrent aspirin therapy (75–325 mg daily).1
Sub-Q
In patients with severe renal impairment (Clcr <30 mL/minute) who are ≥75 years of age: 1 mg/kg once daily (not to exceed 75 mg per dose for the first 2 doses) (no initial direct IV dose) with concurrent aspirin therapy (75–325 mg daily).1
Geriatric Patients
Use with caution; careful attention to dosing intervals and concomitant medications (particularly antiplatelet drugs) advised.1
Manufacturer states that no dosage adjustment necessary in geriatric patients for uses other than STEMI unless renal function is impaired.1
Patients ≥75 years of age with STEMI: 0.75 mg/kg sub-Q every 12 hours (maximum dose 75 mg for each of the first 2 doses only, then 0.75 mg/kg per dose thereafter); do not administer an initial direct IV dose.1 Give in conjunction with aspirin therapy unless contraindicated.1 71
Low-Weight Patients
Carefully monitor for signs and symptoms of bleeding in patients with low body weight (women <45 kg or men <57 kg).1 71
Obese Patients
Safety and efficacy of thromboprophylactic doses in patients with body mass index (BMI) >30 kg/m2 not established; closely monitor for signs and symptoms of thromboembolism in such patients.1
Cautions for Enoxaparin
Contraindications
-
Active major bleeding.1
-
Thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of the drug.1
-
Known hypersensitivity to enoxaparin sodium (e.g., pruritus, urticaria, anaphylactic/anaphylactoid reactions), heparin, pork products, benzyl alcohol, or any ingredient in the formulation.1
Warnings/Precautions
Spinal/Epidural Hematomas
Epidural or spinal hematoma reported with concurrent use of anticoagulants (e.g., LMWHs, heparinoids) and neuraxial (spinal/epidural) anesthesia or spinal puncture procedures.1 161 163 Such hematomas have resulted in neurologic injury, including long-term or permanent paralysis.1 161 (See Boxed Warning.)
Prior to performing a spinal or epidural procedure, determine whether a patient is receiving anticoagulants.161
Carefully consider the timing of spinal catheter placement and removal in relation to anticoagulant use, considering both dosage and pharmacokinetic properties (e.g., elimination half-life) of the anticoagulant.1 161
Insertion or removal of catheter is best performed when the anticoagulant effect of enoxaparin is minimal (e.g., at least 12 hours after a low dose [30 mg once or twice daily or 40 mg once daily] or at least 24 hours after a high dose [0.75 mg/kg twice daily, 1 mg/kg twice daily, or 1.5 mg/kg once daily]).1 161 In patients receiving a twice-daily treatment dosage (0.75 or 1 mg/kg twice daily), omit second dose to allow for a longer delay between doses.1 Consider doubling these recommended time delays in patients with renal impairment.1
Consider delaying subsequent dose of enoxaparin for at least 4 hours after catheter removal based on patient's risk of bleeding versus thrombosis.1 161
Frequently monitor for signs of neurologic impairment (e.g., midline back pain, numbness or weakness in lower limbs, bowel or bladder dysfunction).1 If spinal hematoma suspected, diagnose and treat immediately; consider spinal cord decompression even though it may not prevent or reverse neurologic sequelae.1
Other Warnings Related to Hemorrhage
As with other anticoagulants, bleeding may occur at any site during therapy.1 Major (sometimes fatal) hemorrhages, including retroperitoneal and intracranial bleeding, have been reported.1 Search for bleeding site if an unexplained decrease in hematocrit or BP occurs.1
Use with extreme caution in patients with an increased risk of hemorrhage.1 Such patients include those with bacterial endocarditis; congenital or acquired bleeding disorders; active ulceration and angiodysplastic GI disease; hemorrhagic stroke; or recent brain, spinal, or ophthalmologic surgery.1 Increased risk for hemorrhage in patients treated concomitantly with platelet inhibitors.1
Use with caution in patients with bleeding diathesis, uncontrolled arterial hypertension, or a history of recent GI ulceration, diabetic retinopathy, renal dysfunction, or hemorrhage.1
Periodic CBCs, including platelet counts, and stool occult blood tests recommended.1 If abnormal coagulation parameters or bleeding occurs, may use anti-factor Xa levels to monitor anticoagulant effects of enoxaparin.1
Carefully monitor patients with low body weight or renal impairment for signs and symptoms of bleeding.1
Women treated with an LMWH with or without a GP IIb/IIIa-receptor inhibitor prior to PCI appear to experience more bleeding complications than do men.135
If enoxaparin overdosage occurs, protamine sulfate may be administered.1 Because fatal reactions resembling anaphylaxis have been reported with protamine sulfate administration, use only when resuscitation techniques and treatment for anaphylactic shock are readily available.1
To minimize risk of bleeding during percutaneous revascularization procedures, adhere precisely to recommended dosing intervals.1 Ensure hemostasis at puncture site after PCI; observe for signs of bleeding or hematoma formation.1 If arterial closure device used, may remove sheath immediately; if manual compression used, remove sheath 6 hours after last dose of enoxaparin.1 Administer next scheduled dose no sooner than 6–8 hours after sheath removal.1
Thrombocytopenia
Cases of HIT with thrombosis reported, including complications such as organ infarction, limb ischemia, or death.1 Use with extreme caution in patients with a history of HIT.1 Monitor thrombocytopenia of any degree closely.1 If platelet count falls to <100,000/mm3, discontinue enoxaparin.1
Interchangeability with Other Heparins
Cannot use enoxaparin sodium interchangeably with other LMWHs or heparin sodium because of differences in manufacturing process, molecular weight distribution, anti-factor Xa and anti-factor IIa activities, dosage units, and dosage.1 (See Dosage under Dosage and Administration.)
Patients with Mechanical Prosthetic Heart Valves
Valve thrombosis that resulted in death and/or required surgical intervention reported during prophylaxis in some patients with mechanical prosthetic heart valves, including pregnant women.1 68 69 70 71 82 83 85 87 90 Women with mechanical prosthetic heart valves are at higher risk for thromboembolism during pregnancy.1 85 If enoxaparin is used in pregnant women with mechanical prosthetic heart valves, monitor peak and trough anti-factor Xa concentrations frequently and adjust dosage if necessary to maintain anti-factor Xa levels of 0.7–1.2 units/mL 4 hours after dosing.1 71 82 83 93
Specific Populations
Pregnancy
Category B.1 Because benzyl alcohol may cross the placenta, enoxaparin in multiple-dose vials containing benzyl alcohol should be used with caution and only if clearly needed in pregnant women.1
Maternal and neonatal hemorrhage has occurred; potentially fatal.1 Monitor pregnant women carefully for evidence of bleeding or excessive anticoagulation.1 As delivery approaches, consider use of a shorter-acting anticoagulant.1 (See Boxed Warning.)
Lactation
Not known whether enoxaparin is distributed into breast milk.1 Discontinue nursing or the drug.1 ACCP recommends that LMWHs be continued in nursing women who are already receiving such therapy.1012
Pediatric Use
Safety and efficacy not established.1 17
Large amounts of benzyl alcohol (i.e., 100–400 mg/kg daily) has been associated with toxicity in neonates;1 80 81 each mL of enoxaparin sodium injection in multiple-dose vials contains 15 mg of benzyl alcohol as a preservative.1
Geriatric Use
Use with caution.1 No substantial differences in efficacy relative to younger adults.1 Possible increased risk of bleeding complications.1 Pay careful attention to dosing intervals and concomitant medications (especially antiplatelet medications).1 Consider monitoring (i.e., with anti-factor Xa assay) geriatric patients with low body weight (<45 kg) and those predisposed to decreased renal function.1
Renal Impairment
Use with caution; carefully monitor for manifestations of bleeding.1 Monitor anti-factor Xa concentrations in patients with appreciable renal impairment.1 Hyperkalemia reported in patients with renal failure receiving enoxaparin.1
Decreased clearance.1 Dosage adjustments necessary in patients with severe renal impairment. 1 128 (See Renal Impairment under Dosage and Administration.)
Common Adverse Effects
Elevated serum AST, ALT concentrations, hemorrhage (including at injection site), anemia, fever, peripheral edema.1
Interactions for Enoxaparin
Drugs Affecting Hemostasis
Potential pharmacodynamic interaction with concomitant use of anticoagulants, platelet-aggregation inhibitors, or other drugs affecting hemostasis (increased risk of bleeding complications).1 Use with caution.1
Specific Drugs
Drug |
Interaction |
Comments |
---|---|---|
Anticoagulants |
Increased risk of bleeding1 No pharmacokinetic interaction noted with concomitant administration of thrombolytic agents1 |
If possible, discontinue other anticoagulants prior to initiating enoxaparin1 If concomitant use is essential, careful clinical and laboratory monitoring advised1 |
Aspirin |
Increased risk of bleeding1 |
If possible, discontinue aspirin prior to initiating enoxaparin1 If concomitant use is essential, careful clinical and laboratory monitoring advised1 |
NSAIAs (e.g., ketorolac tromethamine) |
Increased risk of bleeding1 |
If possible, discontinue NSAIAs prior to initiating enoxaparin1 If concomitant use is essential, careful clinical and laboratory monitoring advised1 |
Dipyridamole |
Increased risk of bleeding1 |
If possible, discontinue dipyridamole prior to initiating enoxaparin1 If concomitant use is essential, careful clinical and laboratory monitoring advised1 |
Salicylates |
Increased risk of bleeding1 |
If possible, discontinue salicylates prior to initiating enoxaparin1 If concomitant use is essential, careful clinical and laboratory monitoring advised1 |
Sulfinpyrazone |
Increased risk of bleeding1 |
If possible, discontinue sulfinpyrazone prior to initiating enoxaparin1 If concomitant use is essential, careful clinical and laboratory monitoring advised1 |
Enoxaparin Pharmacokinetics
Absorption
Bioavailability
Mean absolute bioavailability of approximately 100% (based on anti-factor Xa activity) when given sub-Q in healthy individuals.1
Onset
Maximum anti-factor Xa and antithrombin (anti-factor IIa) activities occur 3–5 hours after administration.1
Direct IV injection of 30 mg immediately followed by 1 mg/kg dose sub-Q resulted in postinjection aPTT of 50 seconds.1
Duration
Substantial anti-factor Xa activity persists in plasma for about 12 hours following administration (40 mg once daily).1
Average aPTT prolongation on day 1 about 16% higher than on day 4.1
Distribution
Extent
About 4.3 L (based on anti-factor Xa activity).1
Enoxaparin does not appear to cross the placenta; not known whether the drug is distributed into milk.1
Elimination
Metabolism
Metabolized, principally in the liver via desulfation and/or depolymerization, to less active metabolites.1
Elimination Route
40% of dose is excreted in urine.1
Half-life
4.5 hours after single sub-Q dose, approximately 7 hours after multiple dosing (based on anti-factor Xa activity).1
Special Populations
Clearance reduced in patients with renal impairment.1 In patients with severe renal impairment (Clcr <30 mL/minute), anti-factor Xa exposure (represented by AUC) was increased by approximately 65%.1
Possible delayed elimination and increased exposure in geriatric patients.1 3
Stability
Storage
Parenteral
Solution for Injection
25°C (may be exposed to 15–30°C).1
Compatibility
For information on systemic interactions resulting from concomitant use, see Interactions.
Parenteral
Solution CompatibilityHID
Compatible |
---|
Sodium chloride 0.9% |
Actions
-
Has less effect than heparin on thrombin at a given level of anti-factor Xa activity.1 2 17
-
Prolongs some global clotting function tests (i.e., thrombin time, activated partial thromboplastin time [aPTT]) by up to 1.8 times the control value.1 At a recommended dosage in a large clinical trial, the aPTT was ≤45 seconds in most treated patients.1
Advice to Patients
-
Importance of advising patients who have had neuraxial anesthesia or spinal puncture to monitor for manifestations of spinal or epidural hematoma (e.g., tingling or numbness in lower limbs, muscle weakness), particularly if they are receiving concomitant NSAIAs, platelet-aggregation inhibitors (e.g., clopidogrel), or other anticoagulants; importance of immediately contacting a clinician if any of these symptoms occur.1
-
If therapy is to continue after hospital discharge, importance of instructing patient on proper injection technique of enoxaparin.1
-
Importance of informing patients that they may bruise and/or bleed more easily and that a longer than normal time may be required to stop bleeding when taking enoxaparin.1 Importance of patients reporting any unusual bleeding, bruising, or signs of thrombocytopenia (e.g., dark red spots under skin) to clinician.1
-
Importance of patients informing clinicians (including dentists) that they are receiving enoxaparin therapy before scheduling any invasive procedures.1
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.1
-
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1
-
Importance of informing patients of other important precautionary information. (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Parenteral |
Injection, for subcutaneous use |
10 mg/0.1 mL (30, 40, 60, 80, and 100 mg)* |
Enoxaparin Sodium Injection |
|
Lovenox (available as prefilled disposable syringes) |
Sanofi-Aventis |
|||
15 mg/0.1 mL (120 and 150 mg)* |
Enoxaparin Sodium Injection |
|||
Lovenox (available as disposable prefilled syringes) |
Sanofi-Aventis |
|||
300 mg/3 mL* |
Enoxaparin Sodium Injection |
|||
Lovenox |
Sanofi-Aventis |
AHFS DI Essentials™. © Copyright 2021, Selected Revisions October 23, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
1. Sanofi-Aventis US. Lovenox (enoxaparin sodium) injection prescribing information. Bridgewater, NJ; 2013 Oct.
2. Buckley MM, Sorkin EM. Enoxaparin: A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs. 1992; 44:465-97. http://www.ncbi.nlm.nih.gov/pubmed/1382939?dopt=AbstractPlus
3. Turpie A. Enoxaparin prophylaxis in elective hip surgery. Acta Chir Scand Suppl. 1990; 556:103-107. http://www.ncbi.nlm.nih.gov/pubmed/1963014?dopt=AbstractPlus
4. Fareed J, Walenga JM, Lassen M et al. Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effects. Acta Chir Scand Suppl. 1990; 556:75-90. http://www.ncbi.nlm.nih.gov/pubmed/1963021?dopt=AbstractPlus
5. Hirsh J. From unfractionated heparins to low molecular weight heparins. Acta Chir Scand Suppl. 1990; 556:42-50. http://www.ncbi.nlm.nih.gov/pubmed/1705072?dopt=AbstractPlus
6. Planes A, Vochelle N, Fagola M et al. Once-daily dosing of enoxaparin (a low molecular weight heparin) in prevention of deep-vein thrombosis after total hip replacement. Acta Chir Scand Suppl. 1990; 556:108-15. http://www.ncbi.nlm.nih.gov/pubmed/1963015?dopt=AbstractPlus
7. Planes A, Vochelle N, Mazas F et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988; 60:407-10. http://www.ncbi.nlm.nih.gov/pubmed/2853459?dopt=AbstractPlus
8. Levine MN, Hirsh J, Gent M et al. Prevention of deep-vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991; 114:545- 51. http://www.ncbi.nlm.nih.gov/pubmed/1848054?dopt=AbstractPlus
9. Haas S, Flosbach CW. Prevention of post-operative thromboembolism in general surgery with enoxaparin: preliminary findings. Acta Chir Scand Suppl. 1990; 556:96-102. http://www.ncbi.nlm.nih.gov/pubmed/1963023?dopt=AbstractPlus
10. Spiro TE, Enoxaparin Clinical Trial Group. A randomized trial of enoxaparin administered post operatively for the prevention of deep-vein thrombosis following elective hip replacement surgery. Thromb Haemost. 1991; 65:927.
11. Griffiths MC, ed. USAN 1993: USAN and the USP dictionary of drug names. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1992:238-9.
12. Bara L, Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl. 1990; 556:57- 61. http://www.ncbi.nlm.nih.gov/pubmed/1963018?dopt=AbstractPlus
13. Fareed J, Walenga JM, Hoppensteadt D et al. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci. 1989; 556:333-53. http://www.ncbi.nlm.nih.gov/pubmed/2544128?dopt=AbstractPlus
14. Hoppensteadt D, Racanelli A, Walenga JM et al. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin. Semin Thromb Hemost. 1989; 15:378-85. http://www.ncbi.nlm.nih.gov/pubmed/2530633?dopt=AbstractPlus
15. Fareed J, Walenga JM, Hoppensteadt D et al. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin Thromb Hemost. 1989; 15:440-63. http://www.ncbi.nlm.nih.gov/pubmed/2554505?dopt=AbstractPlus
16. Fareed J, Walenga JM, Williamson K et al. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Semin Thromb Hemost. 1985; 11:56-74. http://www.ncbi.nlm.nih.gov/pubmed/3883500?dopt=AbstractPlus
17. Rhône-Poulenc Rorer, Collegeville, PA: Personal communication.
18. Spiro TE, Colwell CW, Trowbridge AA for the Enoxaparin Clinical Trial Group. A clinical trial comparing the efficacy and safety of enoxaparin, a low molecular weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement surgery.
19. Imperiale TF, Speroff T. A meta-anlysis of methods to prevent venous thromboembolism following total hip replacement. JAMA. 1994; 271:1780-5. http://www.ncbi.nlm.nih.gov/pubmed/7515115?dopt=AbstractPlus
20. Ledere JR, Geerts WH, Desjardins L et al. Prevention of deep-vein thrombosis after major knee surgery—a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost. 1992; 67:417-23. http://www.ncbi.nlm.nih.gov/pubmed/1321509?dopt=AbstractPlus
21. Spiro TE, Colwell CW, Bona RD et al et al. Enoxaparin versus unfractionated heparin for prevention of venous thromboembolic disease after elective knee replacement surgery. Chest. 1994; 106(Suppl 2):48S.
22. Noble S, Peters DH, Goa KL. Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs. 1995; 49:388-410. http://www.ncbi.nlm.nih.gov/pubmed/7774513?dopt=AbstractPlus
24. Heit JA, Berkowitz SD, Bona R et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Thromb Haemost. 1997; 77:32-8. http://www.ncbi.nlm.nih.gov/pubmed/9031445?dopt=AbstractPlus
25. Hull R, Raskob G, Pineo G et al. A comparison of subcutaneous low-molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993; 329:1370-6. http://www.ncbi.nlm.nih.gov/pubmed/8413432?dopt=AbstractPlus
26. Lumpkin MM. Dear health care professional letter regarding reports of epidural or spinal hematomas with concurrent use of low molecular weight heparins or heparinoids and spinal/epidural anesthesia or spinal puncture. Rockville, MD: US Food and Drug Administration; 1997 Dec 15.
27. ENOXACAN Study Group. Efficacy of enoxaparin versus unfractionated heparin for prevention of deep-vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997; 84:1099-103. http://www.ncbi.nlm.nih.gov/pubmed/9278651?dopt=AbstractPlus
28. Dolovich LR, Ginsberg JS, Douketis JD et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med. 2000; 160:181-8. http://www.ncbi.nlm.nih.gov/pubmed/10647756?dopt=AbstractPlus
29. Levine M, Gent M, Hirsch J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996; 334:677-81. http://www.ncbi.nlm.nih.gov/pubmed/8594425?dopt=AbstractPlus
32. Pharmacia & Upjohn, Inc. Fragmin (dalteparin sodium injection) prescribing information. Kalamazoo, MI; 1999 May.
33. Francis CW, Pelligrini VD, Totterman S et al. Prevention of deep-vein thrombosis after total hip arthroplasty: comparison of warfarin and dalteparin. J Bone Joint Surg Am. 1997; 79:1365-72. http://www.ncbi.nlm.nih.gov/pubmed/9314399?dopt=AbstractPlus
34. Spiro TE, Johnson GJ, Christie MJ et al. Efficacy and safety of enoxaparin to prevent deep-vein thrombosis after hip replacement therapy. Ann Intern Med. 1994; 121:81-9. http://www.ncbi.nlm.nih.gov/pubmed/8017740?dopt=AbstractPlus
35. Planes A, Vochelle N, Darmon JY et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement: a prospective randomised double-blind placebo-controlled trial. Drugs. 1996; 52(Suppl 7):47-54. http://www.ncbi.nlm.nih.gov/pubmed/9042560?dopt=AbstractPlus
36. Bergqvist D, Benoni G, Bjorgell O et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996; 335:696-700. http://www.ncbi.nlm.nih.gov/pubmed/8703168?dopt=AbstractPlus
37. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for reginal anesthetic management. Anesth Analg. 1997; 85:874-85. http://www.ncbi.nlm.nih.gov/pubmed/9322474?dopt=AbstractPlus
38. Davidson BL. Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the Swedish study. Chest. 1998; 114(Suppl 2): 130S-2S.
40. Eikelboom JW, Anand SA, Malmberg K et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000; 355:1936-42. http://www.ncbi.nlm.nih.gov/pubmed/10859038?dopt=AbstractPlus
41. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997; 337:447-52. http://www.ncbi.nlm.nih.gov/pubmed/9250846?dopt=AbstractPlus
42. Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999; 100:1593-601. http://www.ncbi.nlm.nih.gov/pubmed/10517729?dopt=AbstractPlus
43. Antman EM, Cohen M, Radley D et al. Asessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation. 1999; 100:1602-8. http://www.ncbi.nlm.nih.gov/pubmed/10517730?dopt=AbstractPlus
44. Armstrong PW. Pursuing progress in acute coronary syndromes. Circulation. 1999; 100:1586-9. http://www.ncbi.nlm.nih.gov/pubmed/10517727?dopt=AbstractPlus
45. Hull RD, Pineo GF, Francis C et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthoplasty patients: a double-blind, randomized comparison. Arch Intern Med. 2000; 160:2199-207. http://www.ncbi.nlm.nih.gov/pubmed/10904464?dopt=AbstractPlus
46. Eriksson BI, Kalebo P, Anthymyr BA et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparions of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am. 1991; 73:484-93. http://www.ncbi.nlm.nih.gov/pubmed/2013587?dopt=AbstractPlus
48. Antman EM, Fox KM for the International Cardiology Forum. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. Am Heart J; 2000;139:461-75.
49. Wallentin L. New trials of LMW heparins-light and heavy weight as good on short but what about longer distances? Eur Heart J. 1999; 20:1522-24.
50. Agency for Health Care Policy and Research. Diagnosing and managing unstable angina. 1994. (AHCPR publication no. 94-0603)
51. Cairns JA, Theroux P, Lewis D et al. Antithrombotic agents in coronary artery disease. Chest. 1998; 114(Suppl 5):611S-33S. http://www.ncbi.nlm.nih.gov/pubmed/9822067?dopt=AbstractPlus
52. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol. 2000; 35:1699-702.
53. Klein W, Buchwald A, Hillis SE et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRISC). Circulation. 1997; 96:61-8. http://www.ncbi.nlm.nih.gov/pubmed/9236418?dopt=AbstractPlus
54. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996; 347:561-8. http://www.ncbi.nlm.nih.gov/pubmed/8596317?dopt=AbstractPlus
55. LeClerc JR, Geerts WH, Desjardins L et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med. 1996; 124:619-26. http://www.ncbi.nlm.nih.gov/pubmed/8607589?dopt=AbstractPlus
56. RD Heparin Arthroplasty Group. RD Heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am. 1994; 76:1174-85. http://www.ncbi.nlm.nih.gov/pubmed/8056798?dopt=AbstractPlus
58. Gould MK, Dembitzer AD, Doyle RL et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep-vein thombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1999; 130:800-9. http://www.ncbi.nlm.nih.gov/pubmed/10366369?dopt=AbstractPlus
64. Bonow RO, Carabello B, de Leon AC et al. ACC/AHA guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol. 1998; 32:1486-588. http://www.ncbi.nlm.nih.gov/pubmed/9809971?dopt=AbstractPlus
66. Mcleod RS,, Geerts WH, Sniderman KW et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery. Results of the Canadian colorectal DVT prophylaxis trials: a randomized, double-blind trial. Ann Surg. 2001; 233: 438-44. http://www.ncbi.nlm.nih.gov/pubmed/11224634?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1421263&blobtype=pdf
67. Samama MM,, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999; 341: 793-800. http://www.ncbi.nlm.nih.gov/pubmed/10477777?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4280563&blobtype=pdf
68. Kramer A, Gurevitch J et al. Low-molecular weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg. 2000; 69:264-6. http://www.ncbi.nlm.nih.gov/pubmed/10654529?dopt=AbstractPlus
69. Rowan JA,, McCowan LM, Raudkivi PJ et al. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol. 2001; 185:633-7. http://www.ncbi.nlm.nih.gov/pubmed/11568791?dopt=AbstractPlus
70. Oles D,, Berryessa R, Campbell K et al. Emergency redo mitral valve replacement in a 27-year-old pregnant female with a clotted prosthetic mitral valve, preoperative fetal demise and postoperative ventricular assist device: a case report. Perfusion. 2001; 16:159-64. http://www.ncbi.nlm.nih.gov/pubmed/11334200?dopt=AbstractPlus
71. Sanofi-Aventis US. Personal communication
72. Cohen M, Bigonzi F et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one year results of the ESSENCE study. Efficacy and safety of subcutaneous enoxaparin in non-Q wave events. J Am Coll Cardiol. 2000; 36:693-8. http://www.ncbi.nlm.nih.gov/pubmed/10987586?dopt=AbstractPlus
76. Yeghiazarians Y, Braunstein JB, Askari A. Unstable angina pectoris. N Engl J Med. 2000; 342:101-14. http://www.ncbi.nlm.nih.gov/pubmed/10631280?dopt=AbstractPlus
77. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494-502. http://www.ncbi.nlm.nih.gov/pubmed/11519503?dopt=AbstractPlus
78. Ridker P, Goldhaber SZ, Danielson E et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med [serial online]. 2003; 348. Available at http://content.nejm.org/cgi/content/abstract/NEJMoa035029v1. Accessed February 24, 2003.
79. Schafer AI. Warfarin for venous thromboembolism—walking the dosing tightrope. N Engl J Med [serial online]. 2003; 348. Editorial. Available at http://content.nejm.org/cgi/content/abstract/NEJMe030018v1. Accessed February 24, 2003.
80. Anon. Benzyl alcohol may be toxic to newborns. FDA Drug Bull. 1982; 12:10-1.
81. American Academy of Pediatrics Committee on Fetus and Newborn and Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. Pediatrics. 1983; 72:356-8. (IDIS 175725) http://www.ncbi.nlm.nih.gov/pubmed/6889041?dopt=AbstractPlus
82. American College of Obstetricians and Gynecologists. ACOG Committee Opinion: safety of lovenox in pregnancy. Obstet Gynecol. 2002;100:845-6.
83. Ginsberg JS, Chan WS, Bates SM et al. Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med. 2003; 163:694-8. http://www.ncbi.nlm.nih.gov/pubmed/12639202?dopt=AbstractPlus
84. Vitale N, De Feo M, Cotrufo M. Anticoagulation for prosthetic heart valves during pregnancy: the importance of warfarin daily dose. Eur J Cardiothorac Surg. 2002; 22:656-7. Letter http://www.ncbi.nlm.nih.gov/pubmed/12297198?dopt=AbstractPlus
85. Leyh RT, Fischer S, Ruhparwar A et al. Anticoagulant therapy in pregnant women with mechanical heart valves. Arch Gynecol Obstet. 2003; 268:1-4 http://www.ncbi.nlm.nih.gov/pubmed/12673466?dopt=AbstractPlus
86. Srivastava AK, Gupta AK, Singh AV et al. Effect of oral anticoagulant during pregnancy with prosthetic heart valve. Asian Cardiovasc Thorac Ann. 2002; 10:306-9 http://www.ncbi.nlm.nih.gov/pubmed/12538273?dopt=AbstractPlus
87. Mahesh B, Evans S, Bryan AJ. Failure of low molecular-weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and a review of options for anticoagulation. J Heart Valve Dis. 2002; 11:745-50 http://www.ncbi.nlm.nih.gov/pubmed/12358414?dopt=AbstractPlus
88. Leyh RG, Fischer S, Ruhparwar A et al. Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular-weight heparin an alternative? Eur J Cardiothorac Surg. 2002; 21:577-9
89. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000; 160:191-6 http://www.ncbi.nlm.nih.gov/pubmed/10647757?dopt=AbstractPlus
90. Berndt N, Khan I, Gallo R. A complication in anticoagulation using low-molecular weight heparin in a patient with a mechanical valve prosthesis. A case report. J Heart Valve Dis. 2000; 9:844-6 http://www.ncbi.nlm.nih.gov/pubmed/11128796?dopt=AbstractPlus
91. Elkayam U. Pregnancy through a prosthetic heart valve. J Am Coll Cardiol. 1999; 33:1642-5. Editorial http://www.ncbi.nlm.nih.gov/pubmed/10334436?dopt=AbstractPlus
92. Meschengieser SS, Fondevila CG, Santarelli MT et al. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart. 1999; 82:23-6 http://www.ncbi.nlm.nih.gov/pubmed/10377303?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1729094&blobtype=pdf
93. Rowan JA, McCowan LM, Raudkivi PJ et al. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol. 2001; 185:633-7 http://www.ncbi.nlm.nih.gov/pubmed/11568791?dopt=AbstractPlus
94. Elkayam UR. Anticoagulation in pregnant women with prosthetic heart valves: a double jeopardy. J Am Coll Cardiol. 1996; 27:1704-6. Editorial http://www.ncbi.nlm.nih.gov/pubmed/8636557?dopt=AbstractPlus
95. Salazar E, Izaguirre R, Verdejo J et al. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J Am Coll Cardiol. 1996; 27:1698-703 http://www.ncbi.nlm.nih.gov/pubmed/8636556?dopt=AbstractPlus
96. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol. 1997; 176:1062-8
97. Schneider DM, Von Tempelhoff G-F, Heilmann L. Retrospective evaluation of the safety and efficacy of low-molecular-weight heparin as thromboprophylaxis during pregnancy. Am J Obstet Gynecol 1997; 177:1567-8. Letter http://www.ncbi.nlm.nih.gov/pubmed/9423786?dopt=AbstractPlus
98. Arnaout MS, Kazma H, Khalil A et al. Is there a safe anticoagulation protocol for pregnant women with prosthetic valves? Clin Exp Obstet Gynecol. 1998; 25:101-4
99. Vitale N, De Feo M, De Santo LS et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999; 33:1637-41 http://www.ncbi.nlm.nih.gov/pubmed/10334435?dopt=AbstractPlus
100. Aventis. Lovenox (enoxaparin sodium) injection prescribing information. Bridgewater, NJ; 2001 Jul.
101. American College of Obstetricians and Gynecologists, Washington, DC. Personal communication.
109. Adams H, Adams R, Del Zoppo G et al. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update. A scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke. 2005; 36:916-21. http://www.ncbi.nlm.nih.gov/pubmed/15800252?dopt=AbstractPlus
110. Adams H, Adams R, Brott T et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003; 34:1056-83. http://www.ncbi.nlm.nih.gov/pubmed/12677087?dopt=AbstractPlus
115. Fox KA, Poole-Wilson PA, Henderson RA. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet. 2002; 360:743-51. http://www.ncbi.nlm.nih.gov/pubmed/12241831?dopt=AbstractPlus
116. Husted SE, Wallentin L, Lagerqvist B et al. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J. 2002; 23:1213-8. http://www.ncbi.nlm.nih.gov/pubmed/12127923?dopt=AbstractPlus
117. Goodman S. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-segment-elevation acute coronary syndrome: insights for the INTERACT trial. Am Heart J. 2005; 149:S73-80. http://www.ncbi.nlm.nih.gov/pubmed/16124951?dopt=AbstractPlus
119. James S, amrstrong P, Califf R et al. Safety and efficacy of abciximab combined with dalteparin in the treatment of acute coronary syndromes. Eur Heart J. 2002; 23:1538-45. http://www.ncbi.nlm.nih.gov/pubmed/12242074?dopt=AbstractPlus
120. Goodman SG, Fitchett D, Armstrong P et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfarctionated heparin in high-risk patients with non-ST-sgement elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003; 107:238-44. http://www.ncbi.nlm.nih.gov/pubmed/12538422?dopt=AbstractPlus
121. Collet JP, Montalescot G, Golmard JL et al. Subcutaneous enoxaparin with early invasive stragety in patients with acute coronary syndromes. Am Heart J. 2004; 147:655-61. http://www.ncbi.nlm.nih.gov/pubmed/15077081?dopt=AbstractPlus
122. Eikelboom JW, Hankey GJ. Low molecular weight heparins and heparinoids. Med J Aust. 2002; 177:379-83. http://www.ncbi.nlm.nih.gov/pubmed/12358583?dopt=AbstractPlus
124. Bhatt DL, Roe MT, Peterson ED et al. Utilization of early invasive management strategies for high-risk patients with non–ST-segment elevation acute coronary syndromes. Results from the CRUSADE Quality Improvement Initiative. JAMA. 2004; 292:2096-2104. http://www.ncbi.nlm.nih.gov/pubmed/15523070?dopt=AbstractPlus
125. Gluckman TJ, Sachdev M, Schulman SP et al. A simplified approach to the management of non–ST-segment elevation acute coronary syndromes. JAMA. 2005; 293:349-357. http://www.ncbi.nlm.nih.gov/pubmed/15657328?dopt=AbstractPlus
126. Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001; 344:1879–87. http://www.ncbi.nlm.nih.gov/pubmed/11419424?dopt=AbstractPlus
127. Braunwald E. Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction. Circulation. 2003; 108[Suppl III]:III-28-37.
128. Hirsh J, Bauer KA, Donati MB et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133:141S-159S. http://www.ncbi.nlm.nih.gov/pubmed/18574264?dopt=AbstractPlus
129. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001; 358:605-13. http://www.ncbi.nlm.nih.gov/pubmed/11530146?dopt=AbstractPlus
130. Wallentin L, Goldstein P, Armstrong PW et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003; 108:135-42. http://www.ncbi.nlm.nih.gov/pubmed/12847070?dopt=AbstractPlus
131. Ross AM, Molhoek P, Lundergan C et al et al. Randomized comparison of enoxaparin, a lowmolecular- weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation. 2001; 104:648-52. http://www.ncbi.nlm.nih.gov/pubmed/11489769?dopt=AbstractPlus
132. Wallentin L, Bergstrand L, Dellborg M et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Eur Heart J. 2003; 24:897-908. http://www.ncbi.nlm.nih.gov/pubmed/12714021?dopt=AbstractPlus
133. Baird SH, Menown IB, Mcbride SJ et al. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J. 2002; 23:627-32. http://www.ncbi.nlm.nih.gov/pubmed/11969277?dopt=AbstractPlus
135. Lansky AJ, Hochman JS, Ward PA et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professional from the American Heart Association. Circulation. 2005; 111:940-3. http://www.ncbi.nlm.nih.gov/pubmed/15687113?dopt=AbstractPlus
136. Mahaffey KW, Ferguson JJ, Califf RM et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004; 292:45-54. http://www.ncbi.nlm.nih.gov/pubmed/15238590?dopt=AbstractPlus
138. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke. 2006; 37:577-617. http://www.ncbi.nlm.nih.gov/pubmed/16432246?dopt=AbstractPlus
142. Wysowski DK, Talarico L, Bacsanyi J et al. Spinal and epidural hematoma and low-molecular-weight heparin. N Engl J Med. 1998; 338:1774. http://www.ncbi.nlm.nih.gov/pubmed/9625640?dopt=AbstractPlus
143. Weitz JI. Low molecular weight heparins. N Engl J Med. 1998; 338:687-8. http://www.ncbi.nlm.nih.gov/pubmed/9490390?dopt=AbstractPlus
146. Wallentin L, Lagerqvist B, Husted S et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet. 2000; 356:9-16. http://www.ncbi.nlm.nih.gov/pubmed/10892758?dopt=AbstractPlus
150. Sanofi-Aventis. Lovenox (enoxaparin sodium) injection prescribing information. Bridgewater, NJ; 2011 Apr.
161. US Food and Drug Administration. FDA drug safety communications: Updated recommendations to decrease risk of spinal column bleeding and paralysis in patients on low molecular weight heparins. 2013 Nov 6. From the FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm373595.htm
162. Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006; 354:1477-88. http://www.ncbi.nlm.nih.gov/pubmed/16537665?dopt=AbstractPlus
163. Horlocker TT, Wedel DJ, Rowlingson JC et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med. 2010 Jan-Feb; 35:64-101.
164. Gibbons RJ, Fuster V. Therapy for patients with acute coronary syndromes—new opportunities. N Engl J Med. 2006; 354:1524-7. Editorial. http://www.ncbi.nlm.nih.gov/pubmed/16537664?dopt=AbstractPlus
165. Morrow DA, Antman EM, Fox KAA et al. One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 Trial. Eur Heart J. 2010; 31:2097–2102.
166. Sanofi-Aventis, Bridgewater, NJ: Personal communication.
167. Gibson CM, Murphy SA, Montalescot G et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007; 49:2238-46. http://www.ncbi.nlm.nih.gov/pubmed/17560287?dopt=AbstractPlus
527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3695607&blobtype=pdf
805. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017; 389:197-210. http://www.ncbi.nlm.nih.gov/pubmed/27502078?dopt=AbstractPlus
991. Anderson JL, Adams CD, Antman EM et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123:e426-579.
994. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58:e44-122. http://www.ncbi.nlm.nih.gov/pubmed/22070834?dopt=AbstractPlus
996. Bonow RO, Carabello BA, Chatterjee K et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008; 118:e523-661.
999. Fuster V, Rydén LE, Cannom DS et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011; 123:e269-367.
1000. Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e152S-84S. http://www.ncbi.nlm.nih.gov/pubmed/22315259?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278055&blobtype=pdf
1001. Kahn SR, Lim W, Dunn AS et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e195S-226S.
1002. Gould MK, Garcia DA, Wren SM et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278061&blobtype=pdf
1003. Falck-Ytter Y, Francis CW, Johanson NA et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e278S-325S. http://www.ncbi.nlm.nih.gov/pubmed/22315265?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278063&blobtype=pdf
1004. Douketis JD, Spyropoulos AC, Spencer FA et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e326S-50S.
1005. Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e419S-94S. http://www.ncbi.nlm.nih.gov/pubmed/22315268?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278049&blobtype=pdf
1006. Linkins LA, Dans AL, Moores LK et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e495S-530S. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278058&blobtype=pdf
1007. You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e531S-75S. http://www.ncbi.nlm.nih.gov/pubmed/22315271?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278056&blobtype=pdf
1008. Whitlock RP, Sun JC, Fremes SE et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e576S-600S. http://www.ncbi.nlm.nih.gov/pubmed/22315272?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278057&blobtype=pdf
1009. Lansberg MG, O'Donnell MJ, Khatri P et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e601S-36S. http://www.ncbi.nlm.nih.gov/pubmed/22315273?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278065&blobtype=pdf
1012. Bates SM, Greer IA, Middeldorp S et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e691S-736S. http://www.ncbi.nlm.nih.gov/pubmed/22315276?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278054&blobtype=pdf
1013. Monagle P, Chan AK, Goldenberg NA et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e737S-801S. http://www.ncbi.nlm.nih.gov/pubmed/22315277?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278066&blobtype=pdf
1017. Bushnell C, McCullough LD, Awad IA et al; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45:1545-88. http://www.ncbi.nlm.nih.gov/pubmed/24503673?dopt=AbstractPlus
1100. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:e344-426. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4676081&blobtype=pdf
HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc; 2007: 616.
More about enoxaparin
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Patient Tips
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- 22 Reviews
- Drug class: heparins
- FDA Alerts (2)
Consumer resources
Professional resources
- Other brands
- Lovenox